Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|March 19, 2020
Lonza Pharma & Biotech
Author(s)Lonza Pharma & Biotech
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable biotech and pharma companies to bring large and small-molecule medicines to patients in need.
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable biotech and pharma companies to bring large and small-molecule medicines to patients in need. From drug substance to the final drug product, our solutions feature concept to commercial capabilities to simplify your outsourcing experience and to provide a reliable outcome when you expect it. Together, we can bring your next medicine to life.
Lonza Pharma & Biotech
Muechensteinstrasse 38 4002 Basel, Switzerland
tel. + 41.61.316 8111
solutions@lonza.com
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5